Besides being produced by immune cells, TRAF1 can be overexpressed by neoplastic cells in different B cell malignancies, and in solid tumors including non-small cell lung cancer for which TRAF1 has been proposed as a biomarker of tumor progression and worst clinical outcome (52–54). Here, TRAF1 is linked to non-small cell lung carcinoma.